Merck Isentress - Emerging Therapy for Treatment of HIV Infection
Key Data:
Drug (brand/generic)
Isentress (raltegravir)
Company/licensee
Merck
Therapy class
Integrase inhibitor
Product description
Anti-retroviral drug that blocks the action of HIV integrase enzyme
Current indication
Treatment of HIV as part of background HIV therapy
Market sector
Anti-infectives
Development status
Approved US; Pre-registration Europe
